和黄医药(00013)启动PI3K/PIKK-EGFR ATTC候选药物HMPL-A580用于治疗实体瘤的全球研究

智通财经03-04

智通财经APP讯，和黄医药(00013)发布公告，和黄医药今日宣布在中国和美国启动和黄医药第二款抗体靶向偶联药物(ATTC)HMPL-A580用于治疗不可切除的晚期或转移性实体瘤的I/IIa期临床试验。首名患者已于2026年3月4日于接受首次给药治疗。HMPL-A580是一款全球首创的的ATTC ，由高选择性、强效的PI3K/PIKK小分子抑制剂作为有效载荷 (payload) ，通过可裂解的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2616319538?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-04 16:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616319538","market":"sh","top_or_hot":-1,"title":"和黄医药(00013)启动PI3K/PIKK-EGFR ATTC候选药物HMPL-A580用于治疗实体瘤的全球研究","media":"智通财经","content":"<div>\n<p>智通财经APP讯，和黄医药(00013)发布公告，和黄医药今日宣布在中国和美国启动和黄医药第二款抗体靶向偶联药物(ATTC)HMPL-A580用于治疗不可切除的晚期或转移性实体瘤的I/IIa期临床试验。首名患者已于2026年3月4日于接受首次给药治疗。HMPL-A580是一款全球首创的的ATTC ，由高选择性 、强效的PI3K/PIKK小分子抑制剂作为有效载荷 (payload) ，通过可裂解的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1409942.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>和黄医药(00013)启动PI3K/PIKK-EGFR ATTC候选药物HMPL-A580用于治疗实体瘤的全球研究</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n和黄医药(00013)启动PI3K/PIKK-EGFR ATTC候选药物HMPL-A580用于治疗实体瘤的全球研究\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-04 16:43 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1409942.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，和黄医药(00013)发布公告，和黄医药今日宣布在中国和美国启动和黄医药第二款抗体靶向偶联药物(ATTC)HMPL-A580用于治疗不可切除的晚期或转移性实体瘤的I/IIa期临床试验。首名患者已于2026年3月4日于接受首次给药治疗。HMPL-A580是一款全球首创的的ATTC ，由高选择性 、强效的PI3K/PIKK小分子抑制剂作为有效载荷 (payload) ，通过可裂解的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1409942.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1587","symbol_name":"次新股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1409942.html","article_id":"2616319538","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616319538","pubTimestamp":1772613817,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，和黄医药 发布公告，和黄医药今日宣布在中国和美国启动和黄医药第二款抗体靶向偶联药物HMPL-A580用于治疗不可切除的晚期或转移性实体瘤的I/IIa期临床试验。这项首个人体试验是一项I/IIa期、开放标签的多中心临床研究，旨在评估HMPL-A580的安全性、耐受性、药代动力学、免疫原性和初步疗效。随后的IIa期剂量扩展/优化阶段将进一步评估HMPL-A580在选定的实体瘤中的安全性、耐受性和初步抗肿瘤活性，并确定下一阶段的建议剂量。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1587":"次新股","BK4585":"ETF&股票定投概念","HCM":"和黄医药","BK1588":"回港中概股","BK1191":"制药","00013":"和黄医药","BK4007":"制药","BK4531":"中概回港概念","BK4588":"碎股"},"translate_title":"Chi-Med (00013) Initiates Global Study of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 for Solid Tumors","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1.5,"HCM":1.5},"content_text":"智通财经APP讯，和黄医药(00013)发布公告，和黄医药今日宣布在中国和美国启动和黄医药第二款抗体靶向偶联药物(ATTC)HMPL-A580用于治疗不可切除的晚期或转移性实体瘤的I/IIa期临床试验。首名患者已于2026年3月4日于接受首次给药治疗。HMPL-A580是一款全球首创的的ATTC ，由高选择性 、强效的PI3K/PIKK小分子抑制剂作为有效载荷 (payload) ，通过可裂解的连接子 (linker)与抗EGFR抗体偶联而成 。这是和黄医药第二款基于该高度创新的PI3K/PIKK抑制剂有效载荷开发的ATTC候选药物。EGFR在多种实体瘤中高表达，被普遍认为是肿瘤发生和疾病进展的重要驱动因素。临床前数据显示，PAM通路抑制与抗EGFR疗法具有协同作用，可增强抗肿瘤活性，相关结果将在即将召开的学术会议上发表。这项首个人体试验是一项I/IIa期、开放标签的多中心临床研究，旨在评估HMPL-A580的安全性、耐受性、药代动力学、免疫原性和初步疗效。研究分为两个阶段。在I期剂量递增阶段，患者将按预先设定的剂量接受HMPL-A580 静脉注射给药，以确定最大耐受剂量(MTD)和剂量扩展推荐剂量(RDE)。随后的IIa期剂量扩展/优化阶段将进一步评估HMPL-A580在选定的实体瘤中的安全性、耐受性和初步抗肿瘤活性，并确定下一阶段的建议剂量。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616319538","isCrawlerRequest":true}